When you’re prescribed a biologic drug, you might not realize you’re being offered two very different options-one that costs tens of thousands of dollars a year, and another that could save you more than half that amount. The difference? It’s not about effectiveness. It’s about cost.
What Exactly Are Brand Biologics and Biosimilars?
Brand biologics are complex drugs made from living cells-like proteins, antibodies, or enzymes. They’re used to treat serious conditions: rheumatoid arthritis, cancer, Crohn’s disease, psoriasis, and more. Think Humira, Enbrel, or Herceptin. These drugs cost a fortune because they’re incredibly hard to make. Even small changes in the manufacturing process can alter how they work. That’s why they’re protected by patents that can last over 12 years.
Biosimilars aren’t generics. That’s a common mistake. Generics are exact chemical copies of simple, small-molecule drugs like aspirin or statins. Biosimilars are highly similar to brand biologics-but not identical. They’re made using living cells too, so tiny variations are unavoidable. But here’s the key: the FDA requires them to perform the same way. Same safety. Same effectiveness. Same side effects. They’re not cheaper because they’re weaker. They’re cheaper because they don’t need to repeat every single expensive clinical trial.
The Real Cost Gap in 2025-2026
In 2025, the average 30-day supply of a brand biologic in the U.S. cost $2,104. The biosimilar version? $919. That’s a 56% drop. For a patient on monthly treatment, that’s over $14,000 saved per year. And it gets better.
Take Humira, the best-selling drug in history. In 2022, its U.S. list price was around $80,000 per patient annually. After biosimilars hit the market in 2023, the original price dropped by 33%-and biosimilars launched at an 80% discount. By mid-2025, biosimilars held 65% of the market for adalimumab. One product alone, Hyrimoz from Sandoz, captured 14% of prescriptions. That’s not a fluke. That’s competition.
Out-of-pocket costs for patients are lower too. A 2025 report from CSRxP found that patients using biosimilars paid 23% less than those on brand biologics. For someone with high-deductible insurance, that could mean the difference between paying $500 or $650 per month.
Why Aren’t More People Using Biosimilars?
Here’s the catch: even though biosimilars are approved, safe, and cheaper, they’re not always the default choice. Why?
First, brand companies don’t give up easily. They pile on patents-not just one or two, but dozens. These "patent thickets" delay biosimilar entry for years. A 2025 DrugPatentWatch analysis showed that brand manufacturers use the same tactics they used against generic small-molecule drugs: filing lawsuits, extending exclusivity, and tweaking formulations just enough to reset the clock.
Second, Pharmacy Benefit Managers (PBMs) often lock in rebates with brand drug makers. If a PBM gets a 20% rebate on a $10,000 drug, they make $2,000 per prescription. If a biosimilar costs $2,000 and offers only a 5% rebate, the PBM makes $100. The math doesn’t favor the patient-it favors the middleman. So even when biosimilars are cheaper, they’re not always pushed.
Third, some doctors and patients still don’t trust them. Misinformation lingers. "It’s not the same," some say. But the FDA, the CDC, and major medical societies have all confirmed: biosimilars are just as safe and effective. In fact, over 76 biosimilars are now approved in the U.S., and none have been pulled for safety issues.
The Big Picture: How Much Have Biosimilars Saved?
Since 2015, biosimilars have saved the U.S. healthcare system between $36 billion and $56 billion, depending on who’s counting. The AAM, a group representing generic and biosimilar manufacturers, says total savings from all generics and biosimilars hit $445 billion in 2023 alone. That’s because generics make up 90% of prescriptions but only 13% of total drug spending.
Biosimilars are still a small slice of that pie-only about 15-20% market share for biologics. Compare that to traditional generics, which drive prices down 79% after competition. Biosimilars haven’t hit that level yet. But they’re getting closer.
And the savings are accelerating. The HHS estimates that if we remove the barriers slowing biosimilar adoption, we could save $42.9 billion in medical costs by 2027. Evaluate Pharma predicts biosimilar market share will jump from 20% to 35-40% by 2030. That could mean over $125 billion in annual savings.
What’s Changing in 2026?
The FDA just released new draft guidance in late 2025 to make biosimilar development faster and cheaper. They’re cutting unnecessary clinical trials-especially for drugs with well-established safety profiles. That means more biosimilars will enter the market sooner.
The Biden administration’s "Biosimilars Action Plan" is pushing for changes in Medicare and Medicaid reimbursement rules to make biosimilars the default option. Some states are already requiring pharmacists to substitute biosimilars unless the doctor says no. And insurance companies are starting to shift formularies to favor them.
Even the big drugmakers are getting in on it. AbbVie, the maker of Humira, now sells its own biosimilar. Why? Because they realized: if you can’t beat them, join them.
What This Means for You
If you’re on a brand biologic, ask your doctor or pharmacist: "Is there a biosimilar available?" If you’re starting treatment, ask: "Is there a lower-cost option?" Don’t assume your prescription is fixed. Many patients don’t realize their insurer might cover a biosimilar at a much lower copay.
Even if your doctor says "it’s not the same," ask for the evidence. The FDA doesn’t approve a biosimilar unless it matches the brand in safety, purity, and potency. That’s not opinion. That’s science.
And if you’re paying out of pocket? Shop around. Prices vary wildly between pharmacies. One pharmacy might offer a biosimilar for $500 a month. Another might charge $1,200 for the brand. That’s a $8,400 difference per year.
Biologics aren’t going away. But their high prices are. The market is changing. The science is clear. The savings are real. And you don’t have to pay more than you have to.
Are biosimilars as safe as brand biologics?
Yes. The FDA requires biosimilars to undergo rigorous testing to prove they’re as safe and effective as the original brand biologic. They must have no clinically meaningful differences in terms of safety, purity, or potency. Over 76 biosimilars have been approved in the U.S. since 2015, and none have been withdrawn for safety reasons. Real-world data from millions of prescriptions confirm they work the same way.
Why are biosimilars cheaper if they’re so similar?
Brand biologics cost billions to develop because they’re made from living cells and require years of clinical trials. Biosimilars don’t need to repeat all those studies. They build on the existing data from the original drug, cutting development time and cost by 70-80%. That savings gets passed on. Plus, competition from multiple biosimilars drives prices down further-just like with generics.
Can my pharmacist switch my brand biologic to a biosimilar without asking me?
It depends on your state and your insurance. In many states, pharmacists can substitute a biosimilar for a brand biologic if it’s deemed interchangeable by the FDA. But some states require the prescriber to approve the switch. Always check your prescription label and ask your pharmacist. If your insurance plan has a formulary that favors biosimilars, you might automatically get one unless your doctor specifies "do not substitute."
Do biosimilars work for all biologic conditions?
Not yet, but they’re expanding fast. As of 2025, biosimilars are approved for conditions like rheumatoid arthritis, Crohn’s disease, psoriasis, certain cancers, and diabetes (insulin). But for newer or rarer biologics-like those for rare autoimmune disorders-biosimilars may not be available yet. The FDA approves them one at a time as patents expire. If your drug is still under patent, a biosimilar won’t be on the market until at least 12 years after the brand launched.
Will my insurance cover a biosimilar?
Most do-especially since 2023. Medicare Part D plans now cover nearly all approved biosimilars. Private insurers are following suit, often requiring patients to try a biosimilar first before approving the brand. Some plans even have higher copays for the brand drug to steer people toward the cheaper option. Always check your plan’s formulary or call your insurer directly. You might be surprised how much you can save.
Write a comment